Locally Advanced Pancreatic Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Only 20% of patients survive 5 years after supposedly curative resection due to the majority of patients eventually developing recurrent illness. Since early symptoms of pancreatic cancer are frequently vague and moderate, approximately 30% of patients have locally advanced pancreatic carcinoma (LAPC) upon arrival, and approximately 50% have metastatic disease. Pancreatic adenocarcinoma, one of the deadliest forms of cancer, is anticipated to overtake lung cancer as the second leading cause of cancer-related deaths in Europe and the US by 2030. With an 8% survival rate after five years, the prognosis hasn't improved much in the past 20 years and is still dire. Gemcitabine (Gem) has been the cornerstone of first-line PDAC treatment for more than ten years. Deflating results have been obtained from numerous attempts to increase the efficacy of single-agent GEMs by combining them with other cytotoxic/molecularly targeted drugs or by changing their pharmacokinetics.

Description

Even after supposedly curative resection, the majority of patients eventually experience recurrent illness, which results in a 5-year survival rate of only 20%. Since early symptoms of pancreatic cancer are frequently vague and moderate, approximately 30% of patients have locally advanced pancreatic carcinoma (LAPC) upon arrival, and approximately 50% have metastatic disease. Only the area around the pancreas is affected by locally advanced pancreatic cancer, which cannot be surgically removed because it has encroached upon or grown close to nearby arteries, veins, or organs. This shows that surgical removal is not an option because there is a high risk of damaging these nearby structures. No evidence suggests that it has spread to other body regions. In between 35 and 40% of cases, this stage is recognized.

Locally Advanced Pancreatic Cancer (Epidemiology)

By 2030, pancreatic adenocarcinoma, one of the deadliest cancers, is anticipated to overtake lung cancer as the second leading cause of cancer-related fatalities in Europe and the US. With an 8% 5-year survival rate, the prognosis hasn't changed much in the last 20 years and is still dire. Surgical resection is the only treatment option that offers a chance of long-term survival and cure. The 11th leading cause of cancer morbidity and the 7th leading cause of cancer-related death worldwide, respectively, is pancreatic cancer. ASR, or average lifetime incidence rate, ranges from 7 to 15. 7 per 100,000 in Europe versus 2 in the U.S. 2 per 100,000 people in Africa. Between 0 and 1, the ASR varied by country. Between the ages of 15 and 24, 81 per 100,000 men in India. 3 per 100,000 men in the Republic of Moldova and Latvia. Approximately 62,210 new cases of pancreatic cancer will be identified in the nation in 2022, according to the American Cancer Society (32,970 men and 29,240 women). From 2010 to 2019, the average annual increase in age-adjusted rates for new cases of pancreatic cancer was 0.5%. Absent risk factors like familial pancreatic cancer and chronic pancreatitis, pancreatic cancer in individuals under the age of 45 is uncommon. After age 50, there is a linear increase in the risk of developing pancreatic cancer. Black people are diagnosed on average at age 65 while White people receive diagnoses on average at age 69. The median age at diagnosis has dropped to 63 years of age for both sexes, according to some single-institution data from significant cancer centers.

Locally Advanced Pancreatic Cancer-Current Market Size & Forecast Trends

The market for locally advanced pancreatic cancer is projected to grow significantly, with estimates indicating a rise from approximately USD 0.9 billion in 2022 to around USD 2.0 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.1% during this period. This growth is driven by the increasing incidence of pancreatic cancer, which is known for its aggressive nature and poor prognosis, as well as advancements in treatment options including chemotherapy, targeted therapies, and immunotherapies. Approximately 30% of pancreatic cancer patients present with locally advanced disease, underscoring the need for effective treatment strategies. The market is also supported by ongoing research and development efforts aimed at improving patient outcomes and expanding therapeutic options. By 2035, the overall pancreatic cancer treatment market, which includes locally advanced cases, is expected to reach about USD 18.7 billion, showcasing a robust CAGR of 14.2% from 2025 to 2035. The combination of rising awareness, increased funding for research, and the development of innovative therapies positions the locally advanced pancreatic cancer market for substantial growth in the coming years.

Gemcitabine (Gem) has been the mainstay of first-line therapy for PDAC for more than ten years. There have been unsuccessful attempts to increase the efficacy of single-agent GEMs by combining them with other cytotoxic/molecularly targeted drugs or by modifying their pharmacokinetics. In the field of systemic therapy for advanced PDAC, advancements have recently been made. When compared to single-agent stones, a number of chemotherapies have demonstrated promising outcomes: regimens like PEFG-PEXG-PDXG and GTX have a significant potential benefit in terms of survival and/or disease control, but occasionally at the expense of poor tolerability. PRODIGE 4/ACCORD 11 was the first phase III study to show a definite benefit of multiple FOLFIRINOX chemotherapy regimens; however, the less favorable safety profile and profile of the enrolled population limit the use of FOLFIRINOX in young, healthy patients with PDAC. To circumvent drug resistance by encasing pancreatic cancer cells in a synthetic matrix, paclitaxel has been conjugated with nanoparticles. Regardless of whether these were the primary mechanisms of action, the combination of nab-paclitaxel and Gem demonstrated a statistically and clinically significant survival advantage over single beads, with significant improvements in all secondary endpoints. Furthermore, new treatment options for advanced PDAC may now be available as a result of recent advancements in maintenance therapy, particularly in this new era of long-lasting disease control made possible by first-line treatment regimens that are extremely effective.

Report Highlights

Locally Advanced Pancreatic Cancer- Current Market Trends

Locally Advanced Pancreatic Cancer- Current & Forecasted Cases across the G8 Countries

Locally Advanced Pancreatic Cancer- Market Opportunities and Sales Potential for Agents

Locally Advanced Pancreatic Cancer- Patient-based Market Forecast to 2035

Locally Advanced Pancreatic Cancer- Untapped Business Opportunities

Locally Advanced Pancreatic Cancer- Product Positioning Vis-a-vis Competitors' Products

Locally Advanced Pancreatic Cancer- KOLs Insight